Genomic variability and natural history of hepatitis C virus infection;Variabilidad genómica e historia natural de la infección por el virus de la hepatitis C

Gastroenterologia y Hepatologia

Volumn 25, Issue 8, 2002, Pages 514-520

  Garcia Retortillo M ^a   Forns, X ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; REVIEW; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 0036822027     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-5705(02)70303-8     Document Type: Review

References (63)

1. Seeff LB. Natural history of hepatitis C. Am J Med 1999;27: 10S-5S.
2. Pagliaro L, Peri V, Linea C, Cammà C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol 1999;31:28-44.
3. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
4. Forns X, Ampurdanès S, Sánchez-Tapias JM, Guilera M, Sans M, Sánchez-Fueyo A, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001;35:265-71.
5. Neyts J, Leyssen P, De Clerq E. Infections with Flaviviridae. Verb K Acad Geneeskd Belg 1999;61:661-97.
6. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997;25:1527-30.
7. He LF, Alling D, Popkin T, Shapiro M, Alter HJ, Purcell RH. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 1987;156:636-40.
8. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Nat Acad Sci USA 1991;88:5547-51.
9. Rüster B, Zeuzem S, Roth WK. Hepatitis C virus sequences encoding truncated core proteins detected in a hepatoc00ellular carcinoma. Biochem Biophys Res Commun 1996;219:911.
10. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4: 1065.
11. Giménez-Barcons M, Franco S, Suárez Y, Forns X, Ampurdanès S, Puig-Basagoiti F, et al. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology 2001;34:158-67.
12. Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 1993;67:6753-61.
13. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-54.
14. Kato N, Ootsuyama Y, Tanaka T, Nakagawa M, Nakazawa T, Muraiso K, et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 1992;22:107-23.
15. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;93:15394.
16. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996;223:409.
17. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995;96:224.
18. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77.
19. Sáiz JC, López-Labrador FX, Ampurdanès S, Dopazo J, Forns X, Sánchez-Tapias JM, et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b ans 3a isolates of hepatitis C virus. J Infect Dis 1998;177:839-47.
20. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991;88:3392-6.
21. Okamoto H, Kojima M, Okada S-I, Yoshizawa H, Iizuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during an 8,2-year infection in a chimpanzee: Variability and stability. Virology 1992;190:894-9.
22. Forns X, Bukh J. Methods for determining the hepatitis C virus genotype. Viral Hepatitis Rev 1998;4:1.
23. Maertens G, Stuyner L. Genotypes and genetic variation of hepatitis C virus. En: Harrison TJ, Zuckerman A, editors. The molecular medicine of viral hepatitis. Medical Science Series. Chichester: John Wiley & Sons, 1997; p. 183.
24. Bukh J, Emerson SU, Purcell RH. Genetic heterogeneity of hepatitis C virus and related viruses. En: Rizzetto M, Purcell RH, Gerin JL, Verme G, editors. Viral hepatitis and liver disease. Turin: Minerva Medica, 1997; p. 167.
25. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66:3225.
26. Purcell RH. Hepatitis C and its sequelae: the biology of hepatitis C virus and implications for its control. En: Kobayashi K, Purcell RH, Shimotohno K, Tabor E, editors. Hepatitis C virus and its involment in the development of hepatocellular carcinoma. Princenton: Princeton Scientific Publishing, 1995; p.1-113.
27. Domingo E, Menéndez-Arias L, Quiñones-Mateu ME, Holguin A, Gutiérrez-Rivas M, Martínez MA, et al. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 1997;48:99-128.
28. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89:3468.
29. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792.
30. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS 1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 1998;27:223-7.
31. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes A, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995; 92:2755-9.
32. Chang KM, Rehermann B, McHutchinson JG, Pasquinelli C, Southwood S, Sette A, Chisari FV. Immunological significance of cytotoxic T lymphocyte epitope variants in patient chronically infected by the hepatitis C virus. J Clin Invest 1997;100:2376-85.
33. Tsai SL, Chen YM, Chen MH, Huang CY, Sheen IS, Yeh CT, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998; 115:954-65.
34. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery fron a single-source outbreak of hepatitis C. Nat Med 2000;6:578-82.
35. Hong Z, Beaudet-Miller M, Landford RE, Guerra B, Wright-Minogue J, Skelton A, et al. Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Virology 1999;256:36-44.
36. Bukh J, Yanagi M, Emerson SU, Purcell RH. Course of infection and evolution of monoclonal hepatitis C virus (HCV) strain H77 in chimpanzees transfected with RNA transcripts from an infectious cDNA clone. Hepatology 1998;28:319A.
37. Major ME, Mihalik K, Fernández J, Seidman J, Kleiner D, Kolykhalov AA, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999;73:3317-25.
38. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 2000;97:13318-23.
39. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-10.
40. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12: 671-5.
41. Tong MJ, al-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion -associated hepatitis C. N Engl J Med 1995; 332:1463-6.
42. Kenny-Walsh E, and the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33.
43. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991;14:969-74.
44. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, et al. Which patients with hepatitis C develop liver complication? Hepatology 2000;31:513-20.
45. Seef LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
46. Farci P, Shimoda A, Coiana A, Díaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-44.
47. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994;20:1144.
48. Polyak SJ, Faulkner G, Carithers RL, Corey L, Gretch DR. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J Infect Dis 1997;175:1101.
49. Kobayashi M, Tanaka E, Sodeyama T, Urushishara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996;23:695-9.
50. Nausbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, and the collaborative study group. Hepatitis C virus 1 b in France and Italy. Ann Intern Med 1995;122:161.
51. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996;111:199.
52. López-Labrador FX, Ampurdanès S, Forns X, Castells A, Sáiz JC, Costa J, et al. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 1997;27:959-65.
53. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis. Hepatology 1997;26(Suppl 1):1225-75.
54. El Zayadi A, Simmonds P, Dabbous H, Prescot L, Selim O, Ahdy A, et al. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996;3:261.
55. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493.
56. McHutchinson JG, Stuart CG, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485.
57. Berenguer M, Wright TL. Hepatitis C and liver transplantation. Gut 1999;45:159-63.
58. Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 2000;7: 87-92.
59. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype lb infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-6.
60. Martell M, Esteban JI, Quer J, Vargas V, Esteban R, Guardia J, et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 1994; 68:3425.
61. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70:7622-31.
62. Laskus T, Wanf LF, Rakela J, Vargas H, Pinna AD, Tsamandas AC, et al. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology 1996;220:171.
63. Okamoto H, Mishiro S, Tokita H, Tsuda F, Miyarama Y, Mayumi M. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/lb with that of genotype III/2a or I/1a. Hepatology 1994;20:1131.